(Total Views: 443)
Posted On: 01/14/2021 12:09:50 PM
Post# of 653
$RLFTF Javitt notes that in their trial enrolled the last patient on December 24, 2020, and they “expect to have the last patient out from the study on January 21, with topline data to follow shortly thereafter.”
The trial’s Data Safety Monitoring Board has reviewed the trial data twice and both times declared it safe to continue. Javitt says, “We expect topline data at the end of the month and that may well trigger regulatory action if we have a positive readout.”
https://www.biospace.com/article/neurorx-on-t...an-javitt/
The trial’s Data Safety Monitoring Board has reviewed the trial data twice and both times declared it safe to continue. Javitt says, “We expect topline data at the end of the month and that may well trigger regulatory action if we have a positive readout.”
https://www.biospace.com/article/neurorx-on-t...an-javitt/
(0)
(0)
$MJ
